Publication Name	World Journal of Critical Care Medicine
Manuscript ID	73238
Country	United States

Received	2021-11-14 19:36
Peer-Review Started	2021-11-14 19:37
To Make the First Decision
Return for Revision	2022-04-07 02:42
Revised	2022-04-23 19:17
Second Decision	2022-06-15 02:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-06-18 21:06
Articles in Press	2022-06-18 21:06
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-06-28 07:06
Publish the Manuscript Online	2022-07-07 10:23

ISSN	2220-3141(online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Critical Care Medicine
Manuscript Type	Minireviews
Article Title	Medicinal nicotine in COVID-19 acute respiratory distress syndrome, the new corticosteroid
Manuscript Source	Unsolicited Manuscript
All Author List	Farrukh Ahmad
ORCID	Author(s) ORCID Number Farrukh Ahmad http://orcid.org/0000-0003-0004-441X
Funding Agency and Grant Number
Corresponding Author	Farrukh Ahmad, MD, Staff Physician, Department of Internal Medicine, Saint Vincent Hospital, 123, Summer Street, Worcester, MA 01608, United States. farrukh2.ahmad@stvincenthospital.com
Key Words	COVID-19; Acute respiratory distress syndrome; Medicinal nicotine; Cholinergic anti-inflammatory pathway; Corticosteroid
Core Tip	Cholinergic anti-inflammatory pathway is novel pathway of the inflammatory reflex. Activation of this pathway can suppress maladaptive inflammatory response seen in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). Nicotine is a potent activator of this pathway and may offer benefits in the management of COVID-19 ARDS, via immune suppressive effects similar to dexamethasone.
Publish Date	2022-07-07 10:23
Citation	Ahmad F. Medicinal nicotine in COVID-19 acute respiratory distress syndrome, the new corticosteroid. World J Crit Care Med 2022; 11(4): 228-235
URL	https://www.wjgnet.com/2220-3141/full/v11/i4/228.htm
DOI	https://dx.doi.org/10.5492/wjccm.v11.i4.228

Full Article (PDF)	WJCCM-11-228.pdf
Full Article (Word)	WJCCM-11-228.docx
Manuscript File	73238_Auto_Edited_LM.docx
Answering Reviewers	73238-Answering reviewers.pdf
Audio Core Tip	73238-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	73238-Conflict-of-interest statement.pdf
Copyright License Agreement	73238-Copyright license agreement.pdf
Peer-review Report	73238-Peer-review(s).pdf
Scientific Misconduct Check	73238-Bing-Gao CC-2.png
Scientific Editor Work List	73238-Scientific editor work list.pdf